Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154332010> ?p ?o ?g. }
- W3154332010 endingPage "974" @default.
- W3154332010 startingPage "961" @default.
- W3154332010 abstract "Abstract While immunotherapy has revolutionized the treatment of many types of advanced cancer, most patients still do not derive benefit. The currently available immune checkpoint inhibitors target the adaptive immune system, generating a T-cell antitumor response. However, an antitumor immune response depends on a complex interplay of both innate and adaptive immune cells. The innate immune system is a promising new target, and innate immune checkpoint inhibitors can disrupt inhibitory interactions (“don't eat me” signals) between tumor and both phagocytes and natural killer cells. The checkpoint inhibitor may also provide a stimulatory interaction (“eat me” signal), or this can be achieved through use of combination therapy. This generates antitumor effector functions including phagocytosis, natural cytotoxicity, antibody-dependent effects, and synergistic activation of the adaptive immune system via antigen presentation. This is a rapidly expanding area of drug development, either alone or in combination (with anticancer antibodies or adaptive immune checkpoint inhibitors). Here, we comprehensively review the mechanism of action and up-to-date solid tumor clinical trial data of the drugs targeting phagocytosis checkpoints (SIRPα/CD47, LILRB1/MHC-I, and LILRB2/MHC-I) and natural killer–cell checkpoints (TIGIT/CD112 + CD155, PVRIG/CD112, KIRs/MHC-I, and NKG2A-CD94/HLA-E). Innate immune checkpoint inhibitors could once again revolutionize immune-based cancer therapies." @default.
- W3154332010 created "2021-04-26" @default.
- W3154332010 creator A5024335038 @default.
- W3154332010 creator A5053908765 @default.
- W3154332010 creator A5056467695 @default.
- W3154332010 creator A5078259926 @default.
- W3154332010 date "2021-04-13" @default.
- W3154332010 modified "2023-10-14" @default.
- W3154332010 title "Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?" @default.
- W3154332010 cites W1966217032 @default.
- W3154332010 cites W1976199086 @default.
- W3154332010 cites W1994993231 @default.
- W3154332010 cites W2018120089 @default.
- W3154332010 cites W2028171968 @default.
- W3154332010 cites W2028487240 @default.
- W3154332010 cites W2047976284 @default.
- W3154332010 cites W2052588575 @default.
- W3154332010 cites W2069621224 @default.
- W3154332010 cites W2081287274 @default.
- W3154332010 cites W2098014710 @default.
- W3154332010 cites W2112400160 @default.
- W3154332010 cites W2113863168 @default.
- W3154332010 cites W2123200946 @default.
- W3154332010 cites W2142541925 @default.
- W3154332010 cites W2150633526 @default.
- W3154332010 cites W2163544987 @default.
- W3154332010 cites W2169656611 @default.
- W3154332010 cites W2221432805 @default.
- W3154332010 cites W2419665234 @default.
- W3154332010 cites W2588178965 @default.
- W3154332010 cites W2588767628 @default.
- W3154332010 cites W2593111137 @default.
- W3154332010 cites W2615301036 @default.
- W3154332010 cites W2626558431 @default.
- W3154332010 cites W2735904407 @default.
- W3154332010 cites W2768892314 @default.
- W3154332010 cites W2782007611 @default.
- W3154332010 cites W2787835497 @default.
- W3154332010 cites W2795318100 @default.
- W3154332010 cites W2795441690 @default.
- W3154332010 cites W2795656758 @default.
- W3154332010 cites W2802206159 @default.
- W3154332010 cites W2808601843 @default.
- W3154332010 cites W2808909747 @default.
- W3154332010 cites W2885785537 @default.
- W3154332010 cites W2888609501 @default.
- W3154332010 cites W2890499629 @default.
- W3154332010 cites W2890786500 @default.
- W3154332010 cites W2892038061 @default.
- W3154332010 cites W2897892714 @default.
- W3154332010 cites W2897898885 @default.
- W3154332010 cites W2898972432 @default.
- W3154332010 cites W2899044337 @default.
- W3154332010 cites W2900891295 @default.
- W3154332010 cites W2902856530 @default.
- W3154332010 cites W2910994117 @default.
- W3154332010 cites W2918786033 @default.
- W3154332010 cites W2919147181 @default.
- W3154332010 cites W2943781197 @default.
- W3154332010 cites W2946946191 @default.
- W3154332010 cites W2947092073 @default.
- W3154332010 cites W2949403516 @default.
- W3154332010 cites W2956922351 @default.
- W3154332010 cites W2971006194 @default.
- W3154332010 cites W2971459028 @default.
- W3154332010 cites W2977255036 @default.
- W3154332010 cites W2977501706 @default.
- W3154332010 cites W2978568563 @default.
- W3154332010 cites W2978986002 @default.
- W3154332010 cites W2979972034 @default.
- W3154332010 cites W2981056570 @default.
- W3154332010 cites W2985006520 @default.
- W3154332010 cites W2987385271 @default.
- W3154332010 cites W3004427843 @default.
- W3154332010 cites W3004907064 @default.
- W3154332010 cites W3004961897 @default.
- W3154332010 cites W3015763287 @default.
- W3154332010 cites W3019532772 @default.
- W3154332010 cites W3023674145 @default.
- W3154332010 cites W3023745224 @default.
- W3154332010 cites W3031115858 @default.
- W3154332010 cites W3031292296 @default.
- W3154332010 cites W3031533147 @default.
- W3154332010 cites W3032062778 @default.
- W3154332010 cites W3049330696 @default.
- W3154332010 cites W3083632537 @default.
- W3154332010 cites W3088018189 @default.
- W3154332010 cites W3088193078 @default.
- W3154332010 cites W3088510493 @default.
- W3154332010 cites W3205998216 @default.
- W3154332010 cites W35202944 @default.
- W3154332010 cites W4206131716 @default.
- W3154332010 cites W4250975267 @default.
- W3154332010 doi "https://doi.org/10.1158/1535-7163.mct-21-0041" @default.
- W3154332010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33850005" @default.
- W3154332010 hasPublicationYear "2021" @default.
- W3154332010 type Work @default.
- W3154332010 sameAs 3154332010 @default.